Screener
BridgeBio Pharma BBIO Debt Repayments
Debt Repayments at other companies
Other financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept us-gaap:RepaymentsOfLinesOfCredit.
The source filing: BridgeBio Pharma’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:31 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001743881-26-000019
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Proceeds from issuance of 2031 Notes | — | 575,000 |
| Issuance costs and discounts associated with 2031 Notes | — | (12,034) |
| Repurchase of common stock | (82,500) | (48,276) |
| Repayment of term loans | — | (459,000) |
| Repayments of deferred royalty obligations (3) | (11,293) | (144) |
| Proceeds from common stock issuances under ESPP | 5,466 | 3,237 |
| Proceeds from stock option exercises, net of repurchases | 22,589 | 2,521 |
| Transactions with noncontrolling interests | — | 800 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is BridgeBio Pharma's debt repayments?
- BridgeBio Pharma (BBIO) reported debt repayments of $0 in Q1 2026.
- How has BridgeBio Pharma's debt repayments changed year-over-year?
- BridgeBio Pharma's debt repayments decreased by 100.0% year-over-year, from $459M to $0.
- What does debt repayments mean?
- Cash used to repay or retire outstanding debt obligations, including scheduled maturities and early redemptions.
Ask your AI about BridgeBio Pharma's debt repayments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude